A Phase II randomized double-blind study of Santostatin LAR in combination with Axitinib versus Placebo in patients with progressive advanced well-differentiated neuroendocrine carcinomas of non-pancreatic origin (carcinoids).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2016
At a glance
- Drugs Axitinib (Primary) ; Octreotide
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 07 Dec 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 07 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.